Volume 7.22 | Jun 11

Mammary Cell News 7.22 June 11, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
Yin and Yang: Immune Signaling Protein Has Opposing Roles in Breast Cancer Development
Researchers have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers. This is because TLR4 can either promote or inhibit breast cancer cell growth depending on mutations in a gene called TP53. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Proceedings of the National Academy of Sciences]
Press Release | Abstract | Full Article
Going to ISSCR 2015? We’ll see you there!
PUBLICATIONS (Ranked by impact factor of the journal)

CCL2-Induced Chemokine Cascade Promotes Breast Cancer Metastasis by Enhancing Retention of Metastasis-Associated Macrophages
Scientists demonstrated that, through activation of the CC-chemokine ligand 2 (CCL2) receptor CCR2, the recruited metastasis-associated macrophages (MAMs) secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice. [J Exp Med] Abstract | Press Release

The Chemokine Receptor CCR6 Facilitates the Onset of Mammary Neoplasia in the MMTV-PyMT Mouse Model via Recruitment of Tumor-Promoting Macrophages
To establish if CCR6 plays a functional role in mammary tumorigenesis, a bigenic MMTV-PyMT CCR6-null mouse was generated and mammary tumor development was assessed. Levels of tumor-infiltrating immune cells within tumor-bearing mammary glands from MMTV-PyMT Ccr6WT and Ccr6-/- mice were also analyzed. [Mol Cancer] Full Article

miR-503 Inhibited Cell Proliferation of Human Breast Cancer Cells by Suppressing CCND1 Expression
The authors aimed to elucidate the role of miR-503 in the pathogenesis of breast cancer. Their results suggested that miR-503 expression was markedly downregulated in breast cancer tissues and cells. [Tumor Biol] Abstract

Hispolon Inhibits the Growth of Estrogen Receptor Positive Human Breast Cancer Cells through Modulation of Estrogen Receptor Alpha
The authors investigated the effects of Hispolon on the growth of breast cancer cells. They found that Hispolon decreased expression of estrogen receptor α at both mRNA and the protein levels in MCF7 and T47D human breast cancer cells. [Biochem Biophys Res Commun] Abstract

Myoepithelial and Luminal Breast Cancer Cells Exhibit Different Responses to All-trans Retinoic Acid
Investigators evaluated whether retinoids may differentially regulate cell type-specific processes associated with breast cancer development using the bi-cellular LM38-LP murine mammary adenocarcinoma cell line as a model. [Cell Oncol] Abstract

Kruppel-Like Factor 4 Signals through MicroRNA-206 to Promote Tumor Initiation and Cell Survival
Researchers found that both expand to Kruppel-like factor 4 and a downstream effector, microRNA-206, are selectively enriched in the mammary cancer stem-like cell (MaCSC) fractions of cultured human triple-negative breast cancer cell lines, as well as in the aldehyde dehydrogenase-high MaCSC sub-population of cells derived from xenografted human mammary carcinomas. [Oncogenesis] Full Article


Randomized Phase III Trial of Paclitaxel Once per Week Compared with Nanoparticle Albumin-Bound Nab-Paclitaxel Once per Week or Ixabepilone with Bevacizumab as First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
Investigators compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer to evaluate progression-free survival for nab-paclitaxel or ixabepilone versus paclitaxel. [J Clin Oncol] Abstract

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Researchers conducted a randomized Phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine to a standard regimen of doxorubicin plus cyclophosphamide followed by docetaxel. [Clin Cancer Res] Abstract

Request a Copy: Breast Cancer Wallchart
The Molecular, Cellular and Clinical Consequences of Targeting the Estrogen Receptor following Estrogen Deprivation Therapy
The current understanding of the mechanism of estrogen-induced apoptosis is described as a consequence of acquired resistance to long term antihormone therapy in estrogen receptor positive breast cancer. [Mol Cell Endocrinol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Cancer Research at Rhode Island Hospital Gets $5.8 Million Boost from the National Institutes of Health
The National Institutes of Health has awarded Rhode Island Hospital $5.8 million to support the hospital’s cancer research program. [Rhode Island Hospital] Press Release

The University Hospital UZ Leuven and Philips Collaborate to Improve Cancer Diagnostics through Digital Pathology
Royal Philips and UZ Leuven, announced a collaboration to digitize and optimize cancer research through digital pathology. The largest university hospital in Belgium will be the first hospital in the country to deploy the Philips IntelliSite Pathology Solution with the aim, through research, to enable faster and more confident diagnosis of cancer and better treatment for patients. [Royal Philips] Press Release

STEMCELL Technologies Named Company of the Year by BIOTECanada
STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO International Convention in Philadelphia. [BIOTECanada] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2015 Midwest Conference on Cell Therapy & Regenerative Medicine
September 18-19, 2015
Kansas City, United States

NEW 6th International Conference on Stem Cells and Cancer (ICSCC-2015): Proliferation, Differentiation and Apoptosis
October 2-5, 2015
Pune, India

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Academic Breast Pathologist (Brigham & Women’s Hospital)

Assistant/Associate/Full Professor – Oncology (Shanghai Jiao Tong University School of Medicine)

Postdoctoral Research Assistant – Role of BRCA1 in the Repair of DNA Damage (University of Dundee)

Postdoctoral Position – Malignant Breast Cancer Cells in the Bone Marrow Microenvironment (Duke University)

Postdoctoral Position – Fatty Acid Metabolism Inhibition on Chemoresistant TNBC Models (University of Girona)

Postdoctoral Fellow – Regulation of Growth and Survival of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us